Report #2870438

Received Nov 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 59 yrs
State: NY
Recovered: Unknown
Vaccinated: Oct 13, 2025
Onset: Oct 13, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (ENGERIX-B)	GLAXOSMITHKLINE BIOLOGICALS	2	y5x9t	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Longer than recommended interval; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 59-year-old female patient who received HBV (Engerix B) (batch number y5x9t, expiry date 30-SEP-2026) for prophylaxis. Previously administered products included Engerix B (received 1st dose on 23 February 2025, batch number y5x9t, expiry date 30 September 2026). On 13-OCT-2025, the patient received the 2nd dose of Engerix B. On 13-OCT-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Longer than recommended interval). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date:14-OCT-2025 The reporter stated that, 2 doses of Engerix-B were given with a longer than recommended interval. The reporter consented to follow up.